Recent Finacing
Recent Raise
Akribion develops a G-dase® nuclease platform using guide RNA to selectively shred intracellular nucleic acids for programmable cell depletion, targeting HPV-driven OPSCC, oncology, autoimmune, fibrosis, and infectious indications.
